Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Lara Grote"'
Autor:
Meletios A. Dimopoulos, Maria T. Petrucci, Robin Foà, John Catalano, Martin Kropff, Evangelos Terpos, Jingshan Zhang, Lara Grote, Christian Jacques, Antonio Palumbo
Publikováno v:
Haematologica, Vol 100, Iss 8 (2015)
Externí odkaz:
https://doaj.org/article/6484867525c7439ebb08d55a72d160ee
Autor:
Maria-Theresa Krauth, Supratik Basu, Philippe Moreau, Lara Grote, Abraham S. Kanate, Paul G. Richardson, Xin Yu, Ercan Muelduer, Peter D. Byeff, Paula Rodriguez-Otero, Paulo Sérgio Lucio, Tsvetan Biyukov, Pekka Anttila, Sujith Dhanasiri, Münci Yağcı, Alessandra Larocca, Meletios A. Dimopoulos, Nicola Cascavilla, Larisa P. Mendeleeva, Marek Hus, Peter R. E. Johnson, Shien Guo, Katja Weisel, Dina Ben-Yehuda, Filiz Vural, Patrick Hayden
Publikováno v:
Leukemialymphoma. 61(8)
In the randomized phase-3 OPTIMISMM study, the addition of pomalidomide to bortezomib and low-dose dexamethasone (PVd) resulted in significant improvement in progression-free survival (PFS) in lenalidomide-pretreated patients with relapsed or refract
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fd5b37af069eab5dc58348df8930f1e
https://pubmed.ncbi.nlm.nih.gov/32268815
https://pubmed.ncbi.nlm.nih.gov/32268815
Autor:
Jesús F. San-Miguel, Meral Beksac, Darrell White, Ruiyun Jiang, Katja Weisel, Albert Oriol, Larry D. Anderson, Alessandra Lorocca, Jindriska Lindsay, Lara Grote, Meletios-Athanasios Dimopoulos, Pawef Robak, Philippe Moreau, Prisca Vogel, Paul G. Richardson, Fredrik Dimopoulos, Teresa Peluso, Anna Marina Liberati
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S163
Background Patients (pts) with multiple myeloma (MM) refractory to lenalidomide (LEN) are a growing and clinically relevant patient population with a need for safe and effective therapies. In the OPTIMISMM trial (NCT01734928), pts with LEN RRMM who w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b8a2e9ed81bfeb7b036927aa68adb20d
https://doi.org/10.1016/s2152-2650(21)02351-x
https://doi.org/10.1016/s2152-2650(21)02351-x
Autor:
Filiz Vural, Meral Beksac, Eva Casal Mendez, Tsvetan Biyukov, Abraham S. Kanate, Pawel Robak, Monica Galli, Lara Grote, Alessandra Larocca, Albert Oriol, Paul G. Richardson, Larry D. Anderson, Katja Weisel, Meletios A. Dimopoulos, Ruiyun Jiang, Jindriska Lindsay, Münci Yağcı, Fredrik Schjesvold, Anna Marina Liberati, Shankar Srinivasan
Publikováno v:
Journal of Clinical Oncology. 38:e20562-e20562
e20562 Background: Upfront LEN until disease progression is a standard treatment (Tx) in multiple myeloma (MM). Data are limited on optimal Tx after first-line LEN, especially in LEN-refractory patients (pts), a growing population. In OPTIMISMM (phas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fc40c0d1787eb2652742df6feae297c6
https://doi.org/10.1200/jco.2020.38.15_suppl.e20562
https://doi.org/10.1200/jco.2020.38.15_suppl.e20562
Autor:
Paul G. Richardson, Lara Grote, Pekka Anttila, Peter R. E. Johnson, Shien Guo, Patrick Hayden, Kosei Matsue, Paula Rodriguez Otero, Philippe Moreau, Marek Hus, Münci Yağcı, Larisa P. Mendeleeva, Ercan Muelduer, Nicola Cascavilla, Lea Purnomo, Katja Weisel, Alessandra Larocca, Maria-Theresa Krauth, Abraham S. Kanate, Dina Ben-Yehuda, Peter D. Byeff, Meletios A. Dimopoulos, Filiz Vural, Mohamed H. Zaki, Tsvetan Biyukov, Xin Yu, Supratik Basu
Publikováno v:
Blood. 132:1960-1960
Introduction : A diagnosis of multiple myeloma (MM) has a substantial impact on health-related quality of life (HRQoL) due to associated symptoms, such as bone pain, infection, and fatigue. Furthermore, HRQoL deteriorates with each subsequent line of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e47cabace718c3e4863c9ef754bdcd7
https://doi.org/10.1182/blood-2018-99-112155
https://doi.org/10.1182/blood-2018-99-112155
Autor:
Antonio Palumbo, Maria Teresa Petrucci, Evangelos Terpos, John Catalano, Lara Grote, Christian Jacques, Robin Foà, Jingshan Zhang, Martin Kropff, Meletios A. Dimopoulos
Maintenance therapy has generally been shown to improve outcomes in newly diagnosed multiple myeloma (NDMM).1–8 Increases in progression-free survival (PFS) and overall survival (OS) have been demonstrated in some trials of maintenance therapy,4–
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd77572076e88e64327618ac36ef4b8c
http://hdl.handle.net/2318/1527058
http://hdl.handle.net/2318/1527058
PFS2 In Elderly Patients With Newly Diagnosed Multiple Myeloma (NDMM): Results From The MM-015 Study
Autor:
John Catalano, Martin Kropff, Antonio Palumbo, Robin Foà, Maria Teresa Petrucci, Lara Grote, Christian Jacques, Meletios A. Dimopoulos, Zhinuan Yu
Publikováno v:
Blood. 122:405-405
Introduction In a phase 3 trial of transplant non-eligible elderly (≥ 65 yrs) patients (pts) with NDMM, the combination of melphalan-prednisone-lenalidomide (LEN) followed by LEN maintenance (MPR-R) reduced the risk of progression by 60% compared w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f545d8226a8794d4e048e17dd348aeb
https://doi.org/10.1182/blood.v122.21.405.405
https://doi.org/10.1182/blood.v122.21.405.405